Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573464 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 559
- Enrollment target
NCT05573464 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 559 participants.
The verdict
NCT05573464, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 559 participants
- Enrollment target
Study Summary
This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
Interventions
- DRUG BGF MDI HFO 320/14.4/9.6 μg
- DRUG BGF MDI HFA 320/14.4/9.6 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2024-03-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05573464
The ClinicalTrials.gov registry entry for NCT05573464 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BGF MDI HFO 320/14.4/9.6 μg is the first listed.
NCT05573464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05573464 about?
NCT05573464 is a clinical study titled "A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
What is the current status of trial NCT05573464?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 559 participants. The study started on 2022-09-27. Estimated completion is 2024-03-26.
What interventions are being tested in trial NCT05573464?
The interventions under investigation include: BGF MDI HFO 320/14.4/9.6 μg (DRUG), BGF MDI HFA 320/14.4/9.6 μg (DRUG).
Who is sponsoring clinical trial NCT05573464?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.